MX2017009812A - Composiciones y metodos para inhibir infeccion viral. - Google Patents

Composiciones y metodos para inhibir infeccion viral.

Info

Publication number
MX2017009812A
MX2017009812A MX2017009812A MX2017009812A MX2017009812A MX 2017009812 A MX2017009812 A MX 2017009812A MX 2017009812 A MX2017009812 A MX 2017009812A MX 2017009812 A MX2017009812 A MX 2017009812A MX 2017009812 A MX2017009812 A MX 2017009812A
Authority
MX
Mexico
Prior art keywords
compositions
methods
viral infection
inhibiting viral
viral
Prior art date
Application number
MX2017009812A
Other languages
English (en)
Inventor
Schlesinger Larry
YOUNT Jacob
ZUKIWSKI Alexander
Proniuk Stefan
Jesús TUÑÓN María
Zandi Keivan
Original Assignee
Arno Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arno Therapeutics Inc filed Critical Arno Therapeutics Inc
Publication of MX2017009812A publication Critical patent/MX2017009812A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Se proporcionan composiciones y métodos para inhibir la producción de proteínas virales, infección viral y replicación viral en un hospedero o células hospederas infectadas con un virus (por ejemplo, influenza, Junina, Chikungunya, Dengue, HIV, RHDV) al administrar AR-12 y análogos de AR-12.
MX2017009812A 2015-01-28 2016-01-27 Composiciones y metodos para inhibir infeccion viral. MX2017009812A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562108960P 2015-01-28 2015-01-28
US201562118766P 2015-02-20 2015-02-20
US201562159129P 2015-05-08 2015-05-08
US201562190706P 2015-07-09 2015-07-09
PCT/US2016/015205 WO2016123259A1 (en) 2015-01-28 2016-01-27 Compositions and methods for inhibiting viral infection

Publications (1)

Publication Number Publication Date
MX2017009812A true MX2017009812A (es) 2018-01-30

Family

ID=56433702

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017009812A MX2017009812A (es) 2015-01-28 2016-01-27 Composiciones y metodos para inhibir infeccion viral.

Country Status (10)

Country Link
US (1) US20160213647A1 (es)
EP (1) EP3250553A4 (es)
JP (1) JP2018506529A (es)
KR (1) KR20170105113A (es)
CN (1) CN107922343A (es)
AU (1) AU2016211546A1 (es)
CA (1) CA2974288A1 (es)
MX (1) MX2017009812A (es)
RU (1) RU2017130031A (es)
WO (1) WO2016123259A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019209035A1 (ko) * 2018-04-27 2019-10-31 주식회사 레모넥스 플라비바이러스 감염증의 예방 또는 치료용 약학적 조성물
EP3785718B1 (en) 2018-04-27 2024-03-27 Lemonex Inc. Pharmaceutical composition for prevention or treatment of flavivirus infectious disease
JP7307412B2 (ja) 2018-06-27 2023-07-12 国立大学法人北海道大学 多環性カルバモイルピリドン誘導体を含有するアレナウイルス増殖阻害剤
CN112772797B (zh) * 2020-12-29 2022-09-27 中国农业科学院蜜蜂研究所 提高蜂王育成量的饲料添加剂及含该饲料添加剂的饲料
CN114668763B (zh) * 2022-03-28 2024-07-23 中国人民解放军海军军医大学 依曲韦林在制备抗蜱传脑炎病毒、西尼罗病毒、黄热病毒和基孔肯雅热病毒感染药物中的应用
CN115400121B (zh) * 2022-04-29 2023-05-23 佛山病原微生物研究院 一种snx-2112在制备用于抗腺病毒感染的药物中的用途
CN114931580B (zh) * 2022-05-26 2024-04-19 军事科学院军事医学研究院军事兽医研究所 依曲韦林在抗狂犬病病毒中的应用和抗狂犬病病毒药物的筛选方法
KR102661593B1 (ko) * 2023-12-06 2024-04-29 대한민국(질병관리청 국립보건연구원장) Osu-03012를 유효성분으로 포함하는 중증열성혈소판감소증후군 예방 또는 치료용 약학 조성물

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040010027A1 (en) * 2001-12-17 2004-01-15 Pharmacia & Upjohn Spa Hydroxphenyl-pyrazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical comositions comprising them
US8039502B2 (en) * 2007-07-24 2011-10-18 The Ohio State University Research Foundation Anti-infective agents against intracellular pathogens

Also Published As

Publication number Publication date
WO2016123259A9 (en) 2017-08-17
US20160213647A1 (en) 2016-07-28
KR20170105113A (ko) 2017-09-18
CA2974288A1 (en) 2016-08-04
CN107922343A (zh) 2018-04-17
AU2016211546A1 (en) 2017-08-17
WO2016123259A1 (en) 2016-08-04
EP3250553A4 (en) 2018-09-12
RU2017130031A (ru) 2019-03-05
EP3250553A1 (en) 2017-12-06
JP2018506529A (ja) 2018-03-08

Similar Documents

Publication Publication Date Title
MX2017009812A (es) Composiciones y metodos para inhibir infeccion viral.
CY1123570T1 (el) Τροποποιητες πυρηνικης πρωτεϊνης ηπατιτιδας β
CY1125368T1 (el) Εμβολια κατα των ιων του αναπνευστικου συστηματος
CY1122291T1 (el) Αναστολeις ιικου αναδιπλασιασμου
BR112018008090A2 (pt) vacina de vírus do herpes simplex.
PH12016501762A1 (en) Hepatitis b core protein allosteric modulators
MX2022009352A (es) Sal de hemisulfato de nucleotido para el tratamiento del virus de hepatitis c.
PH12017501598A1 (en) �-D-2`-DEOXY-2`a-FLUORO-2`-�-C-SUBSTITUTED-2-MODIFIED-N6-SUBSTITUTED PURINE NUCLEOTIDES FOR HCV TREATMENT
BR112018008078A2 (pt) vacina de vírus influenza de amplo espectro
MX2020005187A (es) Compuestos y composiciones farmaceuticas antivirales, asi como metodos de uso de los mismos.
BR112018008102A2 (pt) vacina de vírus sincicial respiratório
MD4589B1 (ro) Compoziţie farmaceutică cu conţinut de sofosbuvir şi utilizarea acesteia în tratamentul hepatitei virale C
MX377983B (es) Análogos de nucleótidos.
GT201500020A (es) Sulfamoilarilamidas y su uso como medicamentos para el tratamiento de la hepatitis b
MX2016004492A (es) Inhibidores de la replicacion del virus de inmunodeficiencia humana (vih).
EA201591287A1 (ru) Вакцины, содержащие стабилизированные тримеры оболочки вируса иммунодефицита человека, и способы их применения
MX383706B (es) Composiciones de cenicriviroc y métodos para elaborarlas y usarlas.
PH12015502230A1 (en) Novel viral replication inhibitors
PH12016500465A1 (en) Deoxynojirimycin derivatives and methods of their using
PH12014500369A1 (en) Influenza h5 vaccines
EP3939604A3 (en) Influenza hemagglutinin protein vaccines
AR101814A1 (es) Partícula de tipo virus flavivirus
MX2017003928A (es) Composiciones farmaceuticas de accion prolongada.
BR112018009946A8 (pt) pró-fármacos de ácido nucleico
WO2014036443A3 (en) Heterocyclyl carboxamides for treating viral diseases